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Poster Session I S309with each of the eight participants. The participants were minor/
young adults who served as a donor for a successful HCT between
January 1999-September 2009. Median donor age at time of HCT
was 13 years (yrs) (range, 2-23 yrs) and the interview 18.5 yrs (range,
13-30 yrs). Median time between donation and interview was 6.5 yrs
(range, 2-10 yrs). Interviews were audio-taped, transcribed, verified,
and de-identified. A grounded theory approach was used to analyze
interview data in aggregate. The sibling world exerts a powerful in-
fluence on shaping the social experiences and problems children will
face across time and development. The transplant experience inten-
sified the sibling donor-recipient bond. Saving my sibling’s life de-
scribed the central phenomenon that captured the memories of
these donors. The life-saving bond reflected the donors’ desires to
help their sibling and keep them in their lives. Five themes unfolded:
a) being the perfect match; b) stepping up; c) worrying about the out-
come; d) the waiting process; and e) sharing a special bond. The first
memory of the donation process centered on beingHLA tested. Par-
ticipants insisted there was no decision about stepping up to be the
donor. They felt immense pressure to be that perfect match to
save their sibling and worried about being the reason their sibling
might die. Participants recalled expecting the donated bone marrow
to take immediate affect, not realizing it takes time for new bone
marrow to function normally. Findings provided new insights into
the complexities of sibling relationships when one has a potentially
life-threatening illness. Interventions targeting this relationship
must be congruent with the cognitive skills and social experiences
of the donor. The quality of the relationship is a critical contextual
factor that provides an entry point for positively impacting adapta-
tion to the donation process and future coping with stressful
situations.281
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Introduction: Chronic Myeloid Leukemia (CML) in pediatrics is
rare. Allogeneic hematopoietic stem cell transplantation (HSCT) is
considered curative treatment for CML. Tyrosine kinase inhibitors
(TKI) are increasingly used as a safe alternative that provide pro-
longed disease control.
Methods:We performed a review of pediatric patients with CML
who received allogeneic HSCT at CMH, Chicago, from
1992-2011.
Results:There were 21 consecutive patients with CML in chronic
phase at the time of HSCT. Mean age at HSCT was 9.6 y (range
0.3 -18 y) and mean time to HSCT from diagnosis was 9.5 m
(range 4-36 m). Eleven (52%) patients did not receive a TKI prior
to HSCT (before 1999). Donors were HLA matched related do-
nors in 9 (43%), HLA matched unrelated donors in 9 (43 %),
and HLA mismatched related donors in 3 (14%). HSC source
was peripheral blood in 9 patients (43%), cord blood in 2 (9.5%),
and bone marrow in 10(47.5%). Fifteen of 21 (71%) patients re-
ceived a myeloablative (MA) conditioning regimen while reduced
intensity conditioning (RIC) regimens were used for 6 (29 %). Me-
dian follow up time post HSCT was 6 y (range 2-17 y). One year
event free survival (EFS) and overall survival (OS) were 60% and
75%, respectively and five-year EFS and OS were 49% and 59%
respectively. All but 2 patients engrafted. Three relapsed (bcr:abl
+), and 8 died secondary to complications. One relapsed patient
and 1 patient with graft failure received a second HSCT. Two re-
lapsed patients went into remission with TKI treatment. Two pa-
tients unsuccesfully received additional donor lymphocyte
infusions for graft failure. Acute ($ grade II) and chronic graft-
versus-host disease (GVHD) was seen in 15 (71%) and 5 (24 %) pa-
tients, respectively. Causes of death included graft failure (n 5 1);
aGVHD (n 5 2); sinusoidal obstruction syndrome (n 5 2); exten-
sive cGVHD (n 5 2) and post transplant lymphoproliferative
disease (n 5 1). On univariate analysis, there was no correlationof outcome with WBC count at diagnosis, time to HSCT, bcr:abl
+ at HSCT, conditioning regimen, prior TKI use, CMV serostatus,
donor type and HLA match, or cell dose.
Conclusions: We conclude that HSCT remains a curative option
for pediatric CML as evidenced by an OS of 59% at 5 years. In
our cohort of CML patients transplant-related mortality and not re-
lapse was the major cause of death. Larger series of patients are
needed to establish a cohort that would benefit fromHSCT upfront
incorporating less toxic conditioning regimens.
Table. Outcomes post HSCT in pediatric CML
Outcome Total N 5 21 MA N 5 15 RIC N 5 6Graft Failure 2 1 1
Acute GVHD 15 10 5
Chronic GVHD 5 2 3
Relapse(bcr:abl +) 3 1 2
Received 2nd Transplant 2 1 1
Mortality + 8 6 2
Mortality 2 13 9 4 (2 alive on TKI)282
EVALUATION OF THE UTILITY OF PRE-HSCT BRAIN MRIS IN PEDIATRIC
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Introduction: Adverse neurological events and new neurological
symptoms (NS) are frequent complications of pediatric hematopoi-
etic stem cell transplant (HSCT). UCSF Benioff Children’s Hospi-
tal routinely obtains pre-HSCT brain MRI in pediatric patients
with hematologic malignancies undergoing HSCT. However the
utility of this standard practice is not well-known. The purpose
of this study is to evaluate risk factors for abnormal pre-HSCT
brain MRI and if surveillance brain MRIs prior to HSCT can pre-
dict NS in post-HSCT period in pediatric patients with hemato-
logic malignancies.
Patients & Methods: Retrospective chart analysis was done in 121
children with a hematological malignancy receiving HSCT (0-22
years) between 2000 and 2009 at UCSF. Nineteen patients were ex-
cluded because they did not undergo pre-HSCT brain MRI or
results were not recorded. Charts were reviewed forNS up to 2-years
post-HSCT. NS included both acute symptoms that resolved and
chronic conditions. A pediatric neurologist reviewed all abnormal
brain MRI reports. Descriptive statistics and two-tailed Fisher’s Ex-
act test were used to analyze the data.
Results:Of the 102 patients included in analysis, 46 patients (45%)
had abnormal brain MRI pre-HSCT. Most common MRI abnor-
malities were white matter changes (n 5 21) and volume loss (n
5 12). The only significant risk factor for abnormal brain MRI
was pre-HSCT neurological symptoms (p\0.001). Multiple risk
factors were not significantly associated with abnormal MRI in-
cluding disease type and presence of pre-HSCT neuropsychologi-
cal symptoms, CNS disease, intrathecal chemotherapy or cranial
radiation. A total of 19 patients (19%) developed new NS during
or post-HSCT. The only significant risk factor for new NS was
conditioning regimen including total body irradiation (TBI) as op-
posed to myeloblative chemotherapy (p 5 0.006). Presence of ab-
normal pre-HSCT MRI was overall not predictive of new NS
during and post-HSCT.
Conclusion: Although many pediatric patients with hematological
malignancies undergoing HSCT have abnormal findings on pre-
HSCT brain MRI, these patients do not have higher likelihood of
developing new neurological symptoms during and post-HSCT.
Surveillance brain MRI pre-HSCT may be useful in patients with
pre-HSCT neurological symptoms to document baseline abnormal-
ities however routine screening of all patients may not be clinically
warranted as a method of predicting neurological sequelae during
and post-HSCT.
